Erytec Pharma : Financial visibility out to Q1 2021
>€ 58.6m of cash at end-March 2020 - Erytech Pharma yesterday evening reported its cash position at end-March 2020, which stands at € 58.6m vs € 73.2m at end-2019. At the rate of cash burn in the quarter (€ 15.3m), this cash position offers financial visibility out to Q1 2021, which should allow the group to deliver on its main trigger in the short term: the intermediate analysis data for TRYbeCA1, its phase III in 2L treatment for pancreatic cancer. To recap, followi...Erytech Pharma is a pharmaceutical company based in France. Co. is primarily engaged in developing cancer therapies that work by starving tumors. Co.'s first product (ERY-ASP), which is in phase III development, provides a therapeutic solution to frail patients with acute leukemia. Co.'s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Co. maintains a production unit located in Lyons with "Pharmaceutical Establishment" status. Co. has also signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.